These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23772929)

  • 1. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.
    Cheadle EJ; Sidon L; Dovedi SJ; Melis MH; Alduaij W; Illidge TM; Honeychurch J
    Br J Haematol; 2013 Sep; 162(6):842-5. PubMed ID: 23772929
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
    Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
    Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.
    Ai L; Ren H; Shi Y; Dong Y
    Int J Hematol; 2008 Jun; 87(5):459-466. PubMed ID: 18414983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.
    Singh V; Gupta D; Arora R; Tripathi RP; Almasan A; Macklis RM
    PLoS One; 2014; 9(11):e111113. PubMed ID: 25364827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
    Alduaij W; Ivanov A; Honeychurch J; Cheadle EJ; Potluri S; Lim SH; Shimada K; Chan CH; Tutt A; Beers SA; Glennie MJ; Cragg MS; Illidge TM
    Blood; 2011 Apr; 117(17):4519-29. PubMed ID: 21378274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.
    Taylor RP; Lindorfer MA
    Blood; 2015 Jan; 125(5):762-6. PubMed ID: 25498911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of anti-CD20 monoclonal antibodies: are we making progress?
    Alduaij W; Illidge TM
    Blood; 2011 Mar; 117(11):2993-3001. PubMed ID: 21209380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
    Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
    Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
    Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
    Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.
    Pérez-Callejo D; González-Rincón J; Sánchez A; Provencio M; Sánchez-Beato M
    Cancer Treat Rev; 2015 Sep; 41(8):680-9. PubMed ID: 26045227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
    Manzur S; Cohen S; Haimovich J; Hollander N
    Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.
    Boross P; Jansen JH; de Haij S; Beurskens FJ; van der Poel CE; Bevaart L; Nederend M; Golay J; van de Winkel JG; Parren PW; Leusen JH
    Haematologica; 2011 Dec; 96(12):1822-30. PubMed ID: 21880632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
    Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
    Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
    Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
    Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP.
    Zhao L; Tong Q; Qian W; Li B; Zhang D; Fu T; Duan S; Zhang X; Zhao J; Dai J; Wang H; Hou S; Guo Y
    Blood; 2013 Dec; 122(26):4230-6. PubMed ID: 24178967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab.
    Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
    J Microsc; 2014 Apr; 254(1):19-30. PubMed ID: 24499016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels.
    Nozaki Y; Mitsumori T; Yamamoto T; Kawashima I; Shobu Y; Hamanaka S; Nakajima K; Komatsu N; Kirito K
    Exp Hematol; 2013 Aug; 41(8):687-696.e1. PubMed ID: 23603515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.